Carolina María Gotera Rivera
Carolina María Gotera Rivera
PULMONOLOGY SPECIALIST
Pulmonologyen/specialities/pulmonology
See more specialists on
Madridmadrid
en/medical-staff/pneumologist
Dr. Carolina María Gotera Rivera is a renowned pulmonologist, currently working as a specialist at the Hospital Universitario Fundación Jiménez Díaz. Her academic background includes a Master's degree in Comprehensive Care of Chronic Obstructive Pulmonary Disease from the Universidad Complutense de Madrid, obtained in 2018. Among her scientific contributions, the publication "European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma," published in October 2023, stands out. Furthermore, Dr. Gotera Rivera was recognized as a finalist for the 2nd SEPAR Award for Best Practices in Healthcare Quality in 2023. She is an active member of the Spanish Society of Pulmonology and Thoracic Surgery, where she contributes to the advancement of respiratory medicine. Her career reflects a constant commitment to excellence in respiratory healthcare.
Key information
- Recognition as a finalist for the II Award for best practices in healthcare quality2023
- Latest Publication:A multicentre, randomized controlled trial of telehealth for the management of COPD.
- Belongs to:Sociedad Española de Neumología y Cirugía Torácica
Professional Details
Hospital Universitario Quirónsalud Madrid
SPECIALIST PHYSICIAN PULMONOLOGY
January 2023
Hospital Universitario Ramón y Cajal
MIR in Pulmonology
May 2010
Study
Bachelor of Medicine and Surgery
Venezuela, Universidad del Zulia
2007
Doctorate
Universidad Alfonso X el Sabio
Specialized Healthcare Training
Pulmonology Specialist
Healthcare Institutions
Another qualification
Master's Degree in Comprehensive Care for Chronic Obstructive Pulmonary Disease
University
Another qualification
Pulmonology Specialist
Spain
Another qualification
Communication course in scientific and health meetings and work situations
Healthcare Institutions
Another qualification
Animal experimentation course for function A
Healthcare Institutions
Another qualification
Animal experimentation course of function D
Healthcare Institutions
Another qualification
Master's degree specializing in Bronchiectasis
University
Another qualification
European Diploma in Adult Respiratory Medicine
ERS
Another qualification
Master's Degree in Clinical Management of Healthcare Units
University
Another qualification
Master's degree in advances in the diagnosis and treatment of airway diseases
University
Another qualification
Animal experimentation course on function C
Healthcare Institutions
Another qualification
Master's Degree in Chronic Obstructive Pulmonary Disease
University
Clinical Teaching Collaborator
Universidad Autónoma de Madrid
January 2016
Observational study for the validation of a questionnaire for physical activity in COPD patients in clinical practice: SAQ-COPD Questionnaire (Spanish activity questionnaire in COPD). AST-SAQ-2017-01 / D2287R00125
AstraZeneca Farmacéutica Spain, S.A.
2019
A phase III, randomized, double-blind, parallel-group, 52-week study comparing the efficacy, safety, and tolerability of the triple fixed-dose combination FF/UMEC/VI with the double fixed-dose combinations FF/VI and UMEC/VI, administered once daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease (IMPACT)
GLAXOSMITHKLLINE (GSK)
2015
Phase IV, observational, multinational study on disease control and patient-reported outcomes treated with fixed-dose combination inhalers for persistent asthma and COPD in routine clinical practice (SPRINT)
TEVA Pharmaceuticals
2015
Roche Cancer Screening Collection Study Protocol No. GO44296
Roche Farma, S.A.
2023
Multicenter multi-dose fevipiprant (QAW039) proof-of-mechanism oral study in patients with COPD and eosinophilia (QAW039E12201)
Novartis Pharmaceuticals, S.A.
2019
PROJECT OncoLung Dx Development of a test for non-invasive early diagnosis of lung cancer based on molecular markers, images and Big Data tools
2022
Phase II, Randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept phase 2a OSCAR study (NCT04376684) assessed the efficacy and safety of a single intravenous infusion of otilimab 90 mg given over an hour or placebo in addition to standard of care
GLAXOSMITHKLLINE (GSK)
2020
A phase 3, randomized, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of SAR440340/REGN3500/itepekimab (anti-IL-33) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). (EFC16819)
Sanofi Aventis
2021
Burden of disease in patients with eosinophilic COPD in Spain: A multicenter observational study
GLAXOSMITHKLLINE (GSK)
2018
A randomized, double-blind (open to sponsor), placebo-controlled, multicenter, dose-finding study to evaluate the efficacy and safety of Danirixin tablets, administered twice daily, compared to placebo for 24 weeks in adult participants with chronic obstructive pulmonary disease (COPD).
GLAXOSMITHKLLINE (GSK)
2017
Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Range Trial to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily with Placental for 24 Weeks in Adult Participants with Chronic Obstructive Pulmonary Disease
GLAXOSMITHKLLINE (GSK)
2017
A 52-week, open-label, multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III trial with an extension to evaluate the efficacy and safety of benralizumab in patients with bronchiectasis not due to cystic fibrosis (MAHALE)
AstraZeneca Pharmaceuticals Spain
2022
A PHASE IIb, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Astegolimab (RO7187807)
Genentech, Inc.
2022
Clinical effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol in a single inhaler (TRELEGY® ELLIPTA®) compared with triple therapies in various non-ELLIPTA devices, in COPD patients in routine clinical practice (INTREPID)
GLAXOSMITHKLLINE (GSK)
2019
Project reference: PI20\01416 Title: Hypoxia markers at the confluence of COPD, OSAHS and Lung Cancer (ECCO Project)
Instituto de Salud Carlos III
2020
Cross-sectional observational descriptive study on the use of LABA and inhaled corticosteroid in a pressurized device in patients with COPD: ARIES Study, protocol code AST-LAB-2017-01 and D589BR00041
AstraZeneca Pharmaceutical
2018
OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related disease.
GLAXOSMITHKLLINE (GSK)
2020
A multicentre, randomized controlled trial of telehealth for the management of COPD.
Scientific article
Current developments and future directions in COPD.
Scientific article
Deep learning-based lesion subtyping and prediction of clinical outcomes in COVID-19 pneumonia using chest CT.
Scientific article
ERS International Congress 2022: highlights from the Airway Diseases Assembly.
Scientific article
European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma.
Scientific article
IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression.
Scientific article
Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience.
Scientific article
Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?.
Scientific article
Metabolomic Signatures of Lung Cancer and Chronic Obstructive Pulmonary Disease.
Scientific article
New Protocol for Evaluating Maximum Inspiratory Pressure: Concurrent Validity and Test-Retest Reliability.
Scientific article
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer.
Scientific article
Sleep apnoea increases biomarkers of immune evasion, lymphangiogenesis and tumour cell aggressiveness in high-risk patients and those with established lung cancer.
Scientific article
Sleep disordered breathing and nocturnal hypoxemia are very prevalent in a lung cancer screening population and may condition lung cancer screening findings: results of the prospective Sleep Apnea In Lung Cancer Screening (SAILS) study.
Scientific article
Treatment and research lines for the patient with COVID-19. What do we have and where are we going.
Scientific article
Untargeted Metabolomic Study of Lung Cancer Patients after Surgery with Curative Intent.
Scientific article
Sociedad Española de Neumología y Cirugía Torácica
European Respiratory Society
Sociedad Madrileña de Neumología y Cirugía Torácica
Recognition as a finalist for the II Award for best practices in healthcare quality
SEPAR
Best Collaborative Service in Research with Residents
Hospital Ramón y Cajal
Second best communication at the XVI congress of the Sociedad madrileña de Neumología
Sociedad Madrileña de Neumología
Spanish
C2
English
B2
Make an appointment with this professional
Vídeos de
Consulta el contenido multimedia de este profesional.
Hospitals
Book an appointment now at one of our hospitals.
Hospital Universitario Quirónsalud Madrid
C/ Diego de Velázquez, 1
28223 Pozuelo de Alarcón Madrid
Articles on
Browse the latest articles on Tu canal de salud.
¿No tienes seguro de salud?
Con nuestros Planes de Salud Quirónsalud Connect tendrás un médico de medicina general todos los días las 24 horas. Y además gestor personal y medición facial de constantes vitales.